Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

CytoMed and SunAct sign agreement for solid tumor treatment trial in India

CytoMed Therapeutics (NASDAQ:GDTC) has announced the signing of a five-year business and research collaboration agreement with the SunAct Cancer Institute to investigate the efficacy, safety, tolerability, and potency...

January 7, 2025

Developments

OraSure’s HIV Self-Test approved for adolescents

OraSure Technologies (NASDAQ:OSUR) has announced that the approved age range for its OraQuick HIV Self-Test has been expanded to include individuals aged 14 and older. The company cites data from the Centers for Disease...

January 7, 2025

Developments

Portage relaunches independent subsidiary with Peter Molloy as CEO

Portage Biotech (NASDAQ:PRTG) has announced the relaunch of its wholly-owned adenosine subsidiary, Cyncado Therapeutics, as an independently managed company headed by Peter Molloy as CEO. The company reports that...

January 6, 2025

Developments

Santhera inks exclusive distribution deal with Clinigen for AGAMREE in DMD

Santhera Pharmaceuticals (SIX:SANN) and closely held Clinigen Group have announced the signing of a supply and distribution agreement that will make AGAMREE accessible to patients with Duchene muscular dystrophy (DMD)...

January 6, 2025

Developments

Clearmind granted patent for binge behavior treatment in Macau

Clearmind Medicine (NASDAQ:CMND; FSE:CWY0) has announced that its proprietary MEAI-based binge behavior regulator program has received patent approval from the Macau International Intellectual Property Office, a special...

January 3, 2025

Developments

Eton acquires rare disease product Galzin

Eton Pharmaceuticals (NASDAQ:ETON) has announced the acquisition of Galzin, a rare disease product used in the treatment of Wilson disease. The company reports that Galzin, an FDA-approved zinc acetate, is utilized as a...

January 3, 2025

Developments

Japan approves SIGA’s antiviral for orthopoxvirus

SIGA Technologies (NASDAQ:SIGA) has announced that its product, TEPOXX, an antiviral therapy targeting orthopoxviruses, has received approval from Japan’s Pharmaceuticals and Medical Devices Agency and the Japan...

January 3, 2025

Markets

Lake Street analyst pitches Profound Medical as one of his ‘best ideas’ for 2025

Lake Street Capital Markets senior research analyst, Ben Haynor, issued a research note today on Profound Medical (NASDAQ:PROF; TSX:PRN), reiterating his ‘buy’ rating and $17 target price on the company’s stock...

January 2, 2025

Executive Moves

Grown Rogue announces Andrew Marchington as CFO and corporate secretary

Grown Rogue (CSE:GRIN; OTC:GRUSF) has appointed Andrew Marchington as its chief financial officer (CFO) and corporate secretary, succeeding Ryan Kee effective January 1, 2025. Previously serving as senior vice president...

January 2, 2025

Executive Moves

Avalo names Jennifer Riley as CSO

Avalo Therapeutics (NASDAQ: AVTX) has announced the appointment of Jennifer Riley as chief strategy officer (CSO), a newly created role effective January 1, 2025. Ms. Riley will oversee corporate strategy, as well as...

January 2, 2025

Executive Moves

Karyopharm appoints Lori Macomber as EVP, CFO, and treasurer

Karyopharm Therapeutics (NASDAQ: KPTI) has announced the appointment of Lori Macomber as executive vice president (EVP), chief financial officer (CFO), and treasurer, effective January 3, 2025. Ms. Macomber, who will be...

January 2, 2025

Executive Moves

Veteran life science equity analyst Chad Messer joins Lake Street Capital Markets

Seasoned life science equity analyst, Chad Messer, Ph.D., has joined Lake Street Capital Markets as a managing director of equity research. Based in New York, Dr. Messer has over two decades of experience spanning...

January 2, 2025

Subscribe